Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer

Area of Science:

• Oncology
• Neurology
• Clinical Trials

Background:

• Taxane-induced peripheral neuropathy (TIPN) significantly impacts cancer patients' quality of life and treatment adherence.
• Effective interventions for preventing and treating TIPN remain limited.

Purpose of the Study:

• To develop and validate a predictive model for identifying patients at risk of developing TIPN.

Main Methods:

• A prospective observational cohort study (SWOG S1714) involving 1278 participants receiving taxane-based chemotherapy.
• A risk prediction model was developed using logistic regression and cross-validation on a training set (n=768) and validated on a test set (n=510).
• TIPN occurrence was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-item scale (CIPN-20) by week 24.

Main Results:

• Over 60% (804 of 1278) of participants experienced TIPN by week 24.
• The validated risk model included factors such as paclitaxel use, advanced disease stage, treatment duration, comorbidities (diabetes, autoimmune disease, kidney disease, neurologic conditions), and patient race/ethnicity.
• The model successfully stratified risk, with high-risk patients experiencing TIPN at a significantly higher rate (68.1%) compared to low-risk patients (50.9%) in the test set.

Conclusions:

• A validated risk prediction model incorporating baseline factors can effectively stratify TIPN risk in cancer patients.
• This model can potentially guide clinical decision-making, enhance symptom monitoring, and inform enrollment in targeted interventional trials for TIPN prevention and management.